148 related articles for article (PubMed ID: 30626961)
1. A father's fight to help his sons - and fix clinical trials.
Adam D
Nature; 2019 Jan; 565(7738):148-151. PubMed ID: 30626961
[No Abstract] [Full Text] [Related]
2. Alkaptonuria - Many questions answered, further challenges beckon.
Davison AS; Hughes AT; Milan AM; Sireau N; Gallagher JA; Ranganath LR
Ann Clin Biochem; 2020 Mar; 57(2):106-120. PubMed ID: 31529982
[No Abstract] [Full Text] [Related]
3. The role of nitisinone in tyrosine pathway disorders.
Lock E; Ranganath LR; Timmis O
Curr Rheumatol Rep; 2014 Nov; 16(11):457. PubMed ID: 25266991
[TBL] [Abstract][Full Text] [Related]
4. Alkaptonuria.
Lorenzini S; Mannoni A; Selvi E
N Engl J Med; 2003 Apr; 348(14):1408; author reply 1408. PubMed ID: 12672874
[No Abstract] [Full Text] [Related]
5. The effect of nitisinone on homogentisic acid and tyrosine: a two-year survey of patients attending the National Alkaptonuria Centre, Liverpool.
Milan AM; Hughes AT; Davison AS; Devine J; Usher J; Curtis S; Khedr M; Gallagher JA; Ranganath LR
Ann Clin Biochem; 2017 May; 54(3):323-330. PubMed ID: 28081634
[TBL] [Abstract][Full Text] [Related]
6. A novel therapeutic trial of homogentisic aciduria in a murine model of alkaptonuria.
Suzuki Y; Oda K; Yoshikawa Y; Maeda Y; Suzuki T
J Hum Genet; 1999; 44(2):79-84. PubMed ID: 10083729
[TBL] [Abstract][Full Text] [Related]
7. Suitability of nitisinone for alkaptonuria.
Häberle J
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):732-733. PubMed ID: 32822593
[No Abstract] [Full Text] [Related]
8. Inhibition of para-Hydroxyphenylpyruvate Dioxygenase by Analogues of the Herbicide Nitisinone As a Strategy to Decrease Homogentisic Acid Levels, the Causative Agent of Alkaptonuria.
Laschi M; Bernardini G; Dreassi E; Millucci L; Geminiani M; Braconi D; Marzocchi B; Botta M; Manetti F; Santucci A
ChemMedChem; 2016 Apr; 11(7):674-8. PubMed ID: 26947423
[TBL] [Abstract][Full Text] [Related]
9. Dietary restriction of tyrosine and phenylalanine lowers tyrosinemia associated with nitisinone therapy of alkaptonuria.
Hughes JH; Wilson PJM; Sutherland H; Judd S; Hughes AT; Milan AM; Jarvis JC; Bou-Gharios G; Ranganath LR; Gallagher JA
J Inherit Metab Dis; 2020 Mar; 43(2):259-268. PubMed ID: 31503358
[TBL] [Abstract][Full Text] [Related]
10. Clinical development innovation in rare diseases: overcoming barriers to successful delivery of a randomised clinical trial in alkaptonuria-a mini-review.
Ranganath LR; Sireau N
Orphanet J Rare Dis; 2023 Jan; 18(1):1. PubMed ID: 36600285
[TBL] [Abstract][Full Text] [Related]
11. Perturbations of tyrosine metabolism promote the indolepyruvate pathway via tryptophan in host and microbiome.
Gertsman I; Gangoiti JA; Nyhan WL; Barshop BA
Mol Genet Metab; 2015 Mar; 114(3):431-7. PubMed ID: 25680927
[TBL] [Abstract][Full Text] [Related]
12. Interference of hydroxyphenylpyruvic acid, hydroxyphenyllactic acid and tyrosine on routine serum and urine clinical chemistry assays; implications for biochemical monitoring of patients with alkaptonuria treated with nitisinone.
Curtis SL; Norman BP; Milan AM; Gallagher JA; Olsson B; Ranganath LR; Roberts NB
Clin Biochem; 2019 Sep; 71():24-30. PubMed ID: 31228435
[TBL] [Abstract][Full Text] [Related]
13. Use of nitisinone in patients with alkaptonuria.
Suwannarat P; O'Brien K; Perry MB; Sebring N; Bernardini I; Kaiser-Kupfer MI; Rubin BI; Tsilou E; Gerber LH; Gahl WA
Metabolism; 2005 Jun; 54(6):719-28. PubMed ID: 15931605
[TBL] [Abstract][Full Text] [Related]
14. Quantification of the flux of tyrosine pathway metabolites during nitisinone treatment of Alkaptonuria.
Milan AM; Hughes AT; Davison AS; Khedr M; Rovensky J; Psarelli EE; Cox TF; Rhodes NP; Gallagher JA; Ranganath LR
Sci Rep; 2019 Jul; 9(1):10024. PubMed ID: 31296884
[TBL] [Abstract][Full Text] [Related]
15. A 3-year randomized therapeutic trial of nitisinone in alkaptonuria.
Introne WJ; Perry MB; Troendle J; Tsilou E; Kayser MA; Suwannarat P; O'Brien KE; Bryant J; Sachdev V; Reynolds JC; Moylan E; Bernardini I; Gahl WA
Mol Genet Metab; 2011 Aug; 103(4):307-14. PubMed ID: 21620748
[TBL] [Abstract][Full Text] [Related]
16. Alkaptonuria: treasure your exceptions.
Cox TM
J Inherit Metab Dis; 2011 Dec; 34(6):1113-4. PubMed ID: 21938512
[No Abstract] [Full Text] [Related]
17. Efficacy and safety of once-daily nitisinone for patients with alkaptonuria (SONIA 2): an international, multicentre, open-label, randomised controlled trial.
Ranganath LR; Psarelli EE; Arnoux JB; Braconi D; Briggs M; Bröijersén A; Loftus N; Bygott H; Cox TF; Davison AS; Dillon JP; Fisher M; FitzGerald R; Genovese F; Glasova H; Hall AK; Hughes AT; Hughes JH; Imrich R; Jarvis JC; Khedr M; Laan D; Le Quan Sang KH; Luangrath E; Lukáčová O; Milan AM; Mistry A; Mlynáriková V; Norman BP; Olsson B; Rhodes NP; Rovenský J; Rudebeck M; Santucci A; Shweihdi E; Scott C; Sedláková J; Sireau N; Stančík R; Szamosi J; Taylor S; van Kan C; Vinjamuri S; Vrtíková E; Webb C; West E; Záňová E; Zatkova A; Gallagher JA
Lancet Diabetes Endocrinol; 2020 Sep; 8(9):762-772. PubMed ID: 32822600
[TBL] [Abstract][Full Text] [Related]
18. Hepatomegaly: commentary.
Rowe S; Pohl JF
Clin Pediatr (Phila); 2005; 44(9):814-6. PubMed ID: 16327972
[No Abstract] [Full Text] [Related]
19. Kidneys of mice with hereditary tyrosinemia type I are extremely sensitive to cytotoxicity.
Jacobs SM; van Beurden DH; Klomp LW; Berger R; van den Berg IE
Pediatr Res; 2006 Mar; 59(3):365-70. PubMed ID: 16492973
[TBL] [Abstract][Full Text] [Related]
20. Nitisinone causes acquired tyrosinosis in alkaptonuria.
Khedr M; Cooper MS; Hughes AT; Milan AM; Davison AS; Norman BP; Sutherland H; Jarvis JC; Fitzgerald R; Markinson L; Psarelli EE; Ghane P; Deutz NEP; Gallagher JA; Ranganath LR
J Inherit Metab Dis; 2020 Sep; 43(5):1014-1023. PubMed ID: 32083330
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
